Cargando…
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer
BACKGROUND: Therapies targeting estrogenic stimulation in estrogen receptor-positive (ER+) breast cancer (BC) reduce mortality, but resistance remains a major clinical problem. Molecular studies have shown few high-frequency mutations to be associated with endocrine resistance. In contrast, expressi...
Autores principales: | Simigdala, Nikiana, Gao, Qiong, Pancholi, Sunil, Roberg-Larsen, Hanne, Zvelebil, Marketa, Ribas, Ricardo, Folkerd, Elizabeth, Thompson, Andrew, Bhamra, Amandeep, Dowsett, Mitch, Martin, Lesley-Ann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888666/ https://www.ncbi.nlm.nih.gov/pubmed/27246191 http://dx.doi.org/10.1186/s13058-016-0713-5 |
Ejemplares similares
-
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
por: Guest, Stephanie K., et al.
Publicado: (2016) -
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022) -
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease
por: Simigdala, Nikiana, et al.
Publicado: (2018) -
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
por: Weigel, Marion T, et al.
Publicado: (2012) -
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
por: Pancholi, Sunil, et al.
Publicado: (2020)